Quantitative analysis of piroxicam using temperature-controlled ionic liquid dispersive liquid phase microextraction followed by stopped-flow injection spectrofluorimetry

Abstract

BACKGROUND: Piroxicam (PXM) belongs to the wide class of non-steroidal anti-inflammatory drugs (NSAIDs). PXM has been widely applied in the treatment of rheumatoid arthritis, gonarthrosis, osteoarthritis, backaches, neuralgia, mialgia. In the presented work, a green and benign sample pretreatment method called temperature-controlled ionic liquid dispersive liquid phase microextraction (TCIL-DLPME) was followed with stopped-flow injection spectrofluorimetry (SFIS) for quantitation of PXM in pharmaceutical formulations and biological samples. METHODS: Temperature-controlled ionic liquid dispersive liquid phase microextraction (TCIL-DLPME) was applied as an environmentally friendly sample enrichment method to extract and isolate PXM prior to quantitation. Dispersion of 1-hexyl-3-methylimidazolium hexafluorophosphate ([Hmim][PF6]) ionic liquid (IL) through the sample aqueous solution was performed by applying a relatively high temperature. PXM was extracted into the extractor, and after phase separation, PXM in the final solution was determined by stopped-flow injection spectrofluorimetry (SFIS). RESULTS AND MAJOR CONCLUSION: Different factors affecting the designed method such as IL amount, diluting agent, pH and temperature were investigated in details and optimized. The method provided a linear dynamic range of 0.2-150 μg l-1, a limit of detection (LOD) of 0.046 μg l-1 and a relative standard deviation (RSD) of 3.1%. Furthermore, in order to demonstrate the analytical applicability of the recommended method, it was applied for quantitation of PXM in real samples.